GLP-1 class side effects: what the trials actually reported
Written by Emily Kang, Beauty & Wellness Editor · Reviewed by Sarah Mitchell, RD, CNS, Lead Reviewer & Registered Dietitian
Last updated November 10, 2026
Last updated November 10, 2026
PeptidesForWeightLossSAFETYSide effectsWhat the trials reportedMatching compound · GLP-2T Vial
Every compound in this class shares the same pattern: digestive effects that rise with dose and cluster in the first months.
Most common
Nausea, diarrhea, vomiting, constipation and reduced appetite. In the trials they were mostly mild to moderate and appeared during dose increases.
Who stopped
| Trial | Group | Stopped due to side effects | Placebo |
|---|---|---|---|
| TRIUMPH-3 (triple) | 9 mg | 9.8% | 4.8% |
| TRIUMPH-3 (triple) | 12 mg | 13.5% | 4.8% |
Less common
The triple agonist trials also reported altered skin sensation and a dose-related rise in heart rate. The approved medicines in this class carry warnings that a prescriber reviews with each patient.
Why this matters
These figures come from supervised trials with slow dose escalation and medical monitoring. Research compounds are not medicines and are sold for laboratory use. Anyone considering treatment should talk to a licensed clinician about an approved product.
⚠️ Research use only. These compounds are sold for laboratory research and are not FDA-approved medicines. Trial figures on this page describe the pharmaceutical molecules studied under medical supervision.